Newbury Pharmaceuticals Q3: Sales Ramp-up - Redeye

Redeye provides a research update following the Q3 report published by Newbury yesterday. We make some slight adjustments to our estimates for operational expenditures, COGS, and net sales. However, we reiterate our fair value range with a base case valuation of SEK8.5 as our outlook on the case remains positive.

Länk till analysen i sin helhet: https://www.redeye.se/research/916301/newbury-pharmaceuticals-q3-sales-ramp-up?utm_source=finwire&utm_medium=RSS